Valencia PD, Arias GNP

Language: Spanish
References: 21
Page: 150-154
PDF size: 556.96 Kb.

ABSTRACT

Fibroblast growth factor 23 (FGF23) is a 251 amino acid secretory hormone, member of the subfamily FGF19. FGF23 is produced in the skeleton in osteoblasts and osteocytes and plays a key role in phosphorus homeostasis regulating in the kidney. The mechanisms of it´s phosphaturic effect are through binding to FGFR receptor and Klotho protein. FGF23 also induces expression of the gene CYP27B1 and CYP24, and acts negatively in the cotransporter NaPi-IIa. In patients with chronic kidney disease high levels FGF23 can be found, which can cause the development of secondary hyperparathyroidism, vitamin D deficiency and hyperphosphatemia. High levels of FGF23 can be a compensatory mechanism to maintain adequate phosphate serum levels, this causes decrease of the 1-alfa-hidroxilase, 1-25 dihydroxycholecalciferol, this active the countervailing mechanisms of the parathyroid gland, and in the end cause “renal osteodystrophy”. High levels of FGF23 are correlated with left ventricular hypertrophy, vascular calcification, and premature mortality.

REFERENCES

1. Yoshiko Y. Mineralized tissue cells are a principal source of FGF23. Bone 2007;40 (5):1565-1573

2. Fukumoto S. FGF23 is a hormone-regulating phosphatemetabolism-Unique biological characteristics of FGF23. Bone 2007;40(05):1190-1195

3. Cheng CY. Whats new in Phosphate Homeostasis? Molecular Regulation of Phosphate Metabolism by Fibroblast Growth Factor-23–Klotho System. ACKD 2011;18(02):91-97

4. Wesseling K. The osteocyte in CKD: New concepts regarding the role of FGF23 in mineral metabolism and systemic complications. Bone 2013;54 (2):222-229

5. Feldman D. FGF23/Klotho New Regulators of Vitamin D Metabolism. En W. Pike, Vitamin D 2011 (págs. 747-761). ELSEVIER.

6. Bhattacharyya N. Fibroblast growth factor 23: state of the field and future directions. Trends in Endocrinology & Metabolism 2012;23(12):610-618

7. Wolf M. Update on Fibroblast Growth Factor 23 in Chronic Kidney Disease. Kidney International 2012;737- 747

8. Lanske. Consequences of changes in FGF23 activity. Bone 2012;50(1):19-29

9. Shanahan CM. Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol. 2013;9:661–670

10. Amanzadeh J. Hypophosphatemia: An Evidence- Based Approach to its Clinical Consequences and Management. Nature 2007;136-1148

11. Olauson H. Parathyroid-Specific Deletion of Klotho Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion. Plos Genetics 2013;9:(12)

12. Donate Correa J. FGF23/Klotho axis: Phosphorus, mineral metabolism and beyond. Cytokine & Growth Factor Reviews 2012;23:37-46

13. Negri A. Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease. Int Urol Nephrol 2013; 46:9-17

14. Martin A. Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis. Adv Exp Med Biol 2012;728:65-83

15. Quarles D. Role of FGF23 in Vitamin D and Phosphate Metabolism: Implications in Chronic Kidney Disease. Exp Cell Res 2012;9:1040-1048

16. Arnlov J. Higher fibroblast growth factor-23 increases the risk of all cause and cardiovascular mortality in the community. Kidney International 2012;8:160-166

17. Olauson H. FGF23 and Klotho in chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22:397-404

18. Hamano T. Fibroblast growth factor 23 and 25- hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. Kidney International Supplements 2013;3:469–475

19. Wesseling-Perry K. The osteocyte in CKD: New concepts regarding the role of FGF23 in mineral metabolism and systemic complications. Bone 2013;54:222–229

20. Diniz H. The role of Fibroblast Growth Factor 23 in Chronic Kidney Disease-mineral and Bone Disorder. Nefrologia 2013;6:835-844

21. Gutierrez O. Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis. N Engl J Med 2008;359:584-592